19d agoStocktwits NewsNEUTRAL 53General
SLS Traders Eye This Important Resistance Zone Ahead Of Key AML Data Readout
Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.
Archived explainer. For the current picture see today's SLS page.
Why Is SELLAS LIFE SCIENCES (SLS) Stock Up Today?
By the Top Tier Newswire AI Desk · August 25, 2026 at 10:07 AM ET · reviewed against 3 wire stories
SELLAS LIFE SCIENCES (SLS) is up +4.86% in the latest session. Our newswire has captured 3 stories on SLS across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
SLS stock rose 4.86% to $15.02 on Monday, driven by speculation around the progress of its Phase 3 REGAL trial for an acute myeloid leukemia treatment. The stock opened with a 0.7% gap up and reached an intraday high of $15.09 before settling near the high at $15.02. Retail traders and market participants are closely watching for data readouts that could validate the trial’s progress, despite the company not yet confirming a key milestone.
What Happened
The stock’s rise came amid reports from a German source suggesting the REGAL trial reached its 80th event, a potential sign of positive progress. While Sellas Life Sciences has not confirmed the claim, the news fueled optimism among traders. The stock has been volatile recently, having fallen 42% from a June high of $15.88 to a July low of $9.19. The current rally follows a 20.8% increase over the last eight sessions, with the price rising from $11.85 to $14.32. Coverage in the last 36 hours has highlighted the upcoming data readout as a major catalyst, with three stories from two sources emphasizing the significance of the trial.
What The Data Shows
The stock traded at 1.5 million shares for the session, which is 0.2 times the 3-month average volume. Call options saw $6.9 million in premium, with the largest single print at $4.1 million. The stock has a market cap of $3.1 billion, a beta of 2.49, and a 52-week range of $1.39 to $15.88. On August 25, the stock printed four fresh 52-week highs and three fresh 52-week lows. The 30-day average sentiment score is 56 out of 100, improving to 62 in the last seven days.
What To Watch
Investors should monitor the upcoming data readout from the Phase 3 REGAL trial, which is expected to provide key insights into the treatment’s efficacy.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SLS by the numbers
Last: $15.02Session: +4.86%7 sessions: +12.72%Coverage: 3 stories / 2 sourcesAI sentiment: 58/100 (bullish)Mkt cap: $3.1B52w: $1.39 to $15.88
The headlines behind the move
19d agoTipRanksBULLISH 63Product/PR
SELLAS Life Sciences Stock (SLS) Has a Major Catalyst on the Horizon
SELLAS Life Sciences stock was a hot topic among retail traders on Monday as the company is getting closer to reporting data from its Phase 3 REGAL trial.
20d agoStocktwits NewsBULLISH 58General
SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced
A German report claimed Regal hit its 80th event, but Sellas has not confirmed it.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on SLS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier SLS move explainers: 2026-08-31 · 2026-08-28 · 2026-08-27 · 2026-08-25 · 2026-08-24 · 2026-08-21 · 2026-08-17